래트 및 마우스 모델 시장 - 세계 예측(2026-2032년)

The Rat & Mouse Model Market is projected to grow by USD 4.74 billion at a CAGR of 8.89% by 2032.

Rat & Mouse Model Executive Summary

Rat and mouse models remain foundational to biomedical research because their genetics, physiology, reproductive efficiency, and well-characterized disease pathways enable reproducible investigation across oncology, immunology, neuroscience, metabolic disorders, cardiovascular disease, infectious disease, toxicology, and pharmacology. The rat and mouse model ecosystem includes inbred, outbred, congenic, transgenic, knockout, knock-in, conditional, humanized, germ-free, gnotobiotic, immunodeficient, and disease-specific strains used in discovery research, preclinical validation, safety assessment, and translational studies. Demand is shaped by the continued need to understand complex biological mechanisms, evaluate therapeutic candidates, and generate evidence required for regulatory submissions while aligning with the 3Rs principles of replacement, reduction, and refinement. Key adoption drivers include CRISPR genome editing, advanced phenotyping, microbiome-controlled models, patient-derived xenograft research, human immune system reconstitution, and increasing use of digital monitoring to reduce stress and improve data quality. At the same time, the landscape is increasingly influenced by ethics review, reproducibility expectations, animal welfare standards, pathogen surveillance, supply-chain resilience, and the integration of non-animal methods where scientifically appropriate. As biomedical pipelines become more targeted and data-intensive, rat and mouse models are evolving from standardized research tools into precision biological platforms that connect genomics, environment, phenotype, and therapeutic response.

Transformative Shifts in the Rat & Mouse Model Landscape

The rat and mouse model landscape is undergoing a structural shift from conventional strain-based research toward precision, human-relevant, and highly controlled experimental systems. CRISPR-based genome editing has accelerated the creation of targeted genetic models, enabling faster development of knockouts, knock-ins, conditional alleles, and models carrying clinically relevant variants. Humanized mouse models are expanding the ability to study immune-oncology, infectious diseases, inflammation, transplantation, and biologics, while rats are gaining renewed importance in neuroscience, cardiovascular research, behavioral studies, toxicology, and surgical models because of their size and physiological suitability. Research organizations are also placing greater emphasis on microbiome standardization, germ-free and gnotobiotic facilities, environmental controls, and genetic quality assurance to address reproducibility concerns documented across preclinical science. Digital vivarium systems, automated home-cage monitoring, telemetry, imaging, and non-invasive biomarkers are transforming endpoint collection by enabling longitudinal data capture and reducing animal handling. Regulatory and funding bodies increasingly expect transparent reporting, appropriate statistical design, consideration of sex as a biological variable, and welfare-focused protocols. These shifts are reshaping procurement and study design decisions, with greater preference for validated models, defined health status, robust metadata, and integrated phenotyping services that support translational relevance.

Cumulative Impact of Artificial Intelligence on Rat & Mouse Models

Artificial intelligence is increasingly influencing the rat and mouse model ecosystem by improving study design, animal welfare monitoring, image analysis, phenotyping, colony management, and translational interpretation. Machine learning tools can analyze behavioral videos, gait patterns, sleep cycles, tumor growth images, histopathology slides, and physiological telemetry to detect subtle phenotypes that may be missed by manual observation. AI-supported experimental design can improve statistical power calculations, reduce unnecessary animal use, and help identify confounding variables such as cage effects, sex differences, microbiome variation, and circadian timing. In vivarium operations, predictive analytics supports breeding optimization, genotype planning, health surveillance, and resource allocation, helping reduce surplus animals and improve colony efficiency. In drug discovery and safety research, AI enables integration of omics data, imaging, pathology, and pharmacodynamic readouts to strengthen cross-species translation and identify signals earlier in the preclinical process. However, AI adoption also raises critical requirements for validated algorithms, explainable outputs, standardized data annotation, bias control, and compliance with animal research governance. The cumulative impact is not the replacement of rat and mouse models in the near term, but the refinement of their use through better data extraction, fewer experimental redundancies, improved welfare, and stronger reproducibility.

Key Regional Insights Across Global Rat & Mouse Model Research

In Asia-Pacific, growth in rat and mouse model research is supported by expanding biomedical infrastructure, national biotechnology programs, increasing translational research activity, and strong academic investment across China, India, Japan, South Korea, Australia, and ASEAN economies. China has become a major hub for genome editing, oncology models, humanized models, and preclinical drug development, while Japan and South Korea emphasize high-quality disease models, regenerative medicine, neuroscience, and biologics research. India is strengthening its contract research, toxicology, vaccine, and pharmacology capabilities, supported by a large scientific workforce and growing regulatory alignment. Australia contributes high standards in animal ethics, immunology, infectious disease, and translational medicine. North America remains one of the most advanced regions for rat and mouse model innovation, driven by extensive biomedical funding, mature vivarium infrastructure, strong regulatory frameworks, and deep expertise in genetically engineered, immunodeficient, and humanized rodent models. The United States is especially influential in cancer biology, neurodegeneration, rare disease, infectious disease, and safety pharmacology, while Canada is recognized for academic research networks, stem cell science, and ethical oversight. Latin America is developing capabilities in pharmacology, infectious disease, metabolic disorders, and toxicology, with Brazil and Mexico serving as important research centers, although infrastructure variability and funding cycles influence adoption. Europe is characterized by rigorous animal welfare regulation, strong implementation of the 3Rs, and advanced research across immunology, neuroscience, oncology, and toxicology, with major contributions from Germany, France, the United Kingdom, Italy, Spain, and other European research economies. The Middle East is investing in biomedical research capacity, genomics, and life science infrastructure, particularly in Gulf economies, while Africa is gradually expanding biomedical and infectious disease research capabilities, with opportunities linked to regional health priorities, training, ethical governance, and international research collaboration.

Key Group Insights Shaping Rat & Mouse Model Adoption

ASEAN is increasingly relevant to rat and mouse model research through expanding biomedical universities, vaccine research, infectious disease programs, and preclinical service capacity in countries with growing life science investment, supported by regional interest in tropical disease, metabolic disorders, and pharmaceutical development. The GCC is strengthening its role through national health research strategies, genomics initiatives, academic medical centers, and investment in laboratory infrastructure, with rat and mouse models supporting diabetes, cardiovascular disease, oncology, and precision medicine studies aligned with regional disease burdens. The European Union provides one of the most structured governance environments for animal research, with harmonized animal welfare legislation, mandatory ethical review, and strong 3Rs implementation that influence study design, reporting, and model selection across member states. BRICS countries represent a diverse and influential grouping for rat and mouse model activity, combining China's large-scale model generation and preclinical research capacity, India's expanding pharmacology and toxicology base, Brazil's infectious disease and metabolic research strengths, Russia's biomedical science legacy, and South Africa's role in regional health research. G7 countries continue to shape global best practices through advanced biomedical funding systems, stringent regulatory expectations, sophisticated disease model development, and strong publication output in translational science. NATO member countries, particularly those with established life science and defense-health research programs, use rat and mouse models in areas such as toxicology, biodefense, infectious disease, trauma, neuroscience, and medical countermeasure development. Across these groups, the defining themes are quality assurance, ethical compliance, genetically defined models, interoperable data, and increasing integration of digital and computational tools.

Key Country Insights for Rat & Mouse Model Research

The United States leads rat and mouse model innovation through extensive biomedical research infrastructure, strong use of genetically engineered models, and advanced applications in oncology, immunology, neuroscience, rare diseases, and toxicology. Canada contributes through high-quality academic research, stem cell biology, neurobiology, infectious disease studies, and robust ethics oversight. Mexico is expanding biomedical and pharmacology research capacity, with rodent models supporting toxicology, metabolic disease, and infectious disease studies. Brazil is a major Latin American contributor, using rat and mouse models in immunology, parasitology, vaccine research, metabolic disorders, and pharmacological evaluation. The United Kingdom is recognized for strong animal welfare governance, neuroscience, cancer research, genetics, and preclinical translational methods, while Germany has deep capabilities in molecular biology, immunology, cardiovascular research, toxicology, and advanced phenotyping. France supports broad rodent model use across oncology, infectious disease, neuroscience, and immunology, aided by major public research institutions and strict ethical review. Russia maintains expertise in biomedical science, pharmacology, physiology, and experimental medicine, although international collaboration dynamics and procurement conditions can affect research flow. Italy and Spain are active in oncology, neuroscience, inflammation, metabolic disease, and pharmacology, with European standards shaping animal use and reporting. China is one of the most dynamic countries for genome-edited, humanized, immunodeficient, and disease-specific mouse and rat models, supported by major investment in biotechnology and translational medicine. India is strengthening its position in toxicology, pharmacology, vaccine research, and disease modeling, driven by its expanding pharmaceutical and academic ecosystem. Japan has long-standing strengths in genetics, aging, neuroscience, immunology, regenerative medicine, and high-quality model development. Australia is prominent in immunology, infectious disease, cancer, and ethical animal research frameworks, while South Korea is advancing rapidly in genome editing, oncology, neuroscience, regenerative medicine, and preclinical research infrastructure. Collectively, these countries illustrate how regulatory standards, funding priorities, disease burden, technical capabilities, and animal welfare expectations shape rat and mouse model utilization.

Actionable Recommendations for Rat & Mouse Model Industry Leaders

Industry leaders should prioritize scientifically justified model selection, ensuring that each rat or mouse model is aligned with the biological mechanism, therapeutic modality, endpoint requirements, and translational objective of the study. Organizations should strengthen reproducibility by implementing genetic authentication, pathogen monitoring, microbiome documentation, standardized housing conditions, sex-balanced study designs where appropriate, and transparent reporting aligned with accepted preclinical research guidelines. Investment in advanced model platforms, including CRISPR-engineered strains, humanized immune system models, patient-derived xenografts, gnotobiotic systems, and longitudinal phenotyping technologies, can improve data relevance while supporting more efficient study execution. Leaders should integrate AI-enabled analytics, automated behavioral assessment, digital pathology, telemetry, and imaging to capture richer datasets and reduce subjective scoring. Animal welfare must remain central, with active adoption of the 3Rs, refined endpoints, non-invasive monitoring, environmental enrichment, and protocol-level review to minimize distress. Supply-chain resilience should be improved through diversified sourcing, cryopreservation strategies, contingency breeding plans, and clear health-status documentation. Finally, decision-makers should build cross-functional teams that connect veterinarians, geneticists, bioinformaticians, pharmacologists, statisticians, and regulatory specialists to improve experimental validity and accelerate translation from preclinical findings to clinical development.

Research Methodology for Rat & Mouse Model Analysis

This executive summary is developed through a structured secondary research approach that prioritizes verified, publicly available, and scientifically credible information. The methodology includes review of peer-reviewed literature, regulatory guidance, animal welfare frameworks, preclinical research reporting standards, biomedical research publications, government and institutional resources, and scientific consensus documents related to rat and mouse model development and use. The analysis considers major model categories, including inbred and outbred strains, genetically engineered models, immunodeficient models, humanized models, disease-specific models, germ-free and gnotobiotic systems, and toxicology models. Regional, group, and country insights are synthesized from observable biomedical research activity, regulatory environments, scientific infrastructure, funding priorities, ethical governance, and life science ecosystem maturity. The research approach avoids unsupported numerical claims, market sizing, market share statements, and forecasting. Emphasis is placed on validated trends such as genome editing adoption, 3Rs implementation, reproducibility requirements, digital phenotyping, AI-enabled analysis, and translational model refinement. Findings are triangulated across multiple categories of evidence to ensure relevance, consistency, and practical value for stakeholders involved in biomedical research, preclinical development, laboratory animal science, and translational medicine.

Conclusion

Rat and mouse models continue to play a critical role in biomedical discovery and preclinical development, while the way they are designed, managed, analyzed, and governed is changing rapidly. The sector is moving toward more precise genetic engineering, improved human relevance, better environmental and microbiome control, stronger ethical oversight, and richer digital phenotyping. Artificial intelligence is reinforcing this evolution by enabling more objective data interpretation, optimized breeding, improved welfare surveillance, and more efficient experimental design. Regional strengths vary, with North America and Europe emphasizing advanced infrastructure and governance, Asia-Pacific accelerating model generation and translational research, Latin America building capacity around regional disease priorities, and the Middle East and Africa expanding biomedical capabilities through targeted investment and collaboration. For industry leaders, success depends on combining high-quality models with rigorous study design, transparent reporting, animal welfare excellence, and data-driven decision-making. As non-animal methods, organoids, organ-on-chip systems, and computational models advance, rat and mouse models will increasingly be used in integrated evidence frameworks rather than in isolation. The future of the rat and mouse model landscape will be defined by scientific validity, ethical responsibility, reproducibility, and the ability to generate translational insights that support safer and more effective therapies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Rat & Mouse Model Market, by Species

• 7.1. Introduction
• 7.2. Rat Models
  • 7.2.1. Outbred Rat Models
  • 7.2.2. Inbred Rat Models
  • 7.2.3. Genetically Engineered Rat Models
  • 7.2.4. Immunodeficient Rat Models
• 7.3. Mouse Models
  • 7.3.1. Outbred Mouse Models
  • 7.3.2. Inbred Mouse Models
  • 7.3.3. Genetically Engineered Mouse Models
    • 7.3.3.1. Knockout Mouse Models
    • 7.3.3.2. Transgenic Mouse Models
    • 7.3.3.3. Humanized Mouse Models
  • 7.3.4. Immunodeficient Mouse Models
    • 7.3.4.1. Nude Mouse Models
    • 7.3.4.2. SCID Mouse Models
    • 7.3.4.3. NOG/NSG Mouse Models

8. Rat & Mouse Model Market, by Model Type

• 8.1. Introduction
• 8.2. Inbred Models
• 8.3. Outbred Models
• 8.4. Genetically Engineered Models
  • 8.4.1. Knockout Models
    • 8.4.1.1. Constitutive Knockout Models
    • 8.4.1.2. Conditional Knockout Models
    • 8.4.1.3. Inducible Knockout Models
  • 8.4.2. Transgenic Models
  • 8.4.3. Humanized Models
  • 8.4.4. Knock-in Models
• 8.5. Xenograft Models
  • 8.5.1. Cell Line-Derived Xenograft Models
  • 8.5.2. Patient-Derived Xenograft Models
• 8.6. Syngeneic Models
• 8.7. Chemically Induced Models
• 8.8. Diet-Induced Models
• 8.9. Surgically Induced Models
• 8.10. Spontaneous Disease Models
• 8.11. Reporter Models

9. Rat & Mouse Model Market, by Service Type

• 9.1. Introduction
• 9.2. Standard Model Supply
  • 9.2.1. Live Animals
  • 9.2.2. Cryopreserved Embryos & Sperm
• 9.3. Custom Model Generation
  • 9.3.1. Gene Editing Design & Construction
  • 9.3.2. Embryology & Microinjection Services
  • 9.3.3. Validation & Quality Control
• 9.4. Breeding & Colony Management
  • 9.4.1. Breeding Strategy Design
  • 9.4.2. Colony Expansion & Maintenance
  • 9.4.3. Health Monitoring
• 9.5. Cryopreservation & Recovery
  • 9.5.1. Sperm Cryopreservation
  • 9.5.2. Embryo Cryopreservation
  • 9.5.3. Resuscitation Services
• 9.6. Rederivation & Health Status Improvement
• 9.7. Phenotyping & Behavior Testing
  • 9.7.1. Physiological Phenotyping
  • 9.7.2. Behavioral & Cognitive Testing
• 9.8. In Vivo Study Services
  • 9.8.1. Efficacy Studies
  • 9.8.2. Disease Induction & Monitoring
  • 9.8.3. Surgical Modeling
• 9.9. Consulting & Regulatory Support

10. Rat & Mouse Model Market, by Application

• 10.1. Introduction
• 10.2. Drug Discovery & Screening
  • 10.2.1. Target Identification & Validation
  • 10.2.2. High-Throughput Screening
  • 10.2.3. Lead Optimization
• 10.3. Preclinical Efficacy Studies
  • 10.3.1. Dose-Response Studies
  • 10.3.2. Combination Therapy Studies
• 10.4. Pharmacokinetics & Pharmacodynamics
  • 10.4.1. Absorption, Distribution, Metabolism & Excretion
  • 10.4.2. Exposure-Response Modeling
• 10.5. Safety & Toxicology Testing
  • 10.5.1. Acute Toxicity
  • 10.5.2. Chronic Toxicity
  • 10.5.3. Carcinogenicity
  • 10.5.4. Reproductive & Developmental Toxicity
• 10.6. Disease Mechanism & Pathophysiology Research
• 10.7. Biomarker Discovery & Validation
• 10.8. Translational & Biomimetic Studies
• 10.9. Education & Training

11. Rat & Mouse Model Market, by End User

• 11.1. Introduction
• 11.2. Pharmaceutical Companies
  • 11.2.1. Top-Tier & Multinational Pharma
  • 11.2.2. Mid-Size & Specialty Pharma
• 11.3. Biotechnology Companies
  • 11.3.1. Established Biotech Firms
  • 11.3.2. Emerging & Virtual Biotech
• 11.4. Contract Research Organizations
  • 11.4.1. Global CROs
  • 11.4.2. Niche Preclinical CROs
• 11.5. Academic & Research Institutes
  • 11.5.1. Universities
  • 11.5.2. Independent Research Institutes
• 11.6. Government & Public Sector Laboratories
• 11.7. Nonprofit & Foundations
• 11.8. Industry Consortia & Partnerships

12. Rat & Mouse Model Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Rat & Mouse Model Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Rat & Mouse Model Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Biocytogen Pharmaceuticals Co., Ltd.
• 16.2. Champions Oncology, Inc.
• 16.3. Charles River Laboratories International, Inc.
• 16.4. Crown Bioscience International, Inc.
• 16.5. Cyagen Biosciences, Inc.
• 16.6. Envigo RMS, LLC
• 16.7. GemPharmatech Co., Ltd.
• 16.8. genOway S.A.
• 16.9. Harbour BioMed
• 16.10. Hera BioLabs, Inc.
• 16.11. inGenious Targeting Laboratory, Inc.
• 16.12. Janvier Labs SA
• 16.13. Oncodesign Precision Medicine
• 16.14. Oriental BioService Co., Ltd.
• 16.15. Ozgene Pty Ltd.
• 16.16. PerkinElmer, Inc.
• 16.17. Pharmatest Services Oy
• 16.18. PolyGene AG
• 16.19. Taconic Biosciences, Inc.
• 16.20. The Jackson Laboratory
• 16.21. TransCure bioServices
• 16.22. TransTech Pharma, Inc.
• 16.23. TransViragen, Inc.
• 16.24. Vivo Bio Tech Ltd.